Materials Transfer Agreement Sample Contracts

Share Cite Term
Link

Embed (HTML)
Metastat Inc – Information for Which Confidential Treatment Has Been Requested Is Omitted and Marked With "****" or Otherwise Clearly Indicated. An Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Pilot Materials Transfer Agreement (October 6th, 2016)

This Pilot Materials Transfer Agreement ("Agreement") is made and entered into as of August 22, 2016 ("EFFECTIVE DATE") by and among Celgene Corporation, a Delaware corporation having a place of business at 85 Morris Avenue, Summit, NJ, 07901 (together with its subsidiaries and affiliates, hereinafter collectively referred to as "Celgene"), and MetaStat, Inc., a Nevada corporation having an address at 27 Drydock Ave., 2nd Floor, Boston, MA 02210-2377 ("Company").

Metastat Inc – Confidential Treatment Requested. Information for Which Confidential Treatment Has Been Requested Is Omitted and Marked With "****" or Otherwise Clearly Indicated. An Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. First Amendment to Pilot Materials Transfer Agreement (October 6th, 2016)

This is an amendment ("First Amendment"), effective as of September 29, 2016 ("First Amendment Effective Date"), to the Pilot Materials Transfer Agreement ( "Agreement") by and between Celgene Corporation, a Delaware corporation having its principal place of business at 86 Morris Avenue, Summit, New Jersey 07901 (together with its subsidiaries and affiliates hereinafter collectively referred to as "Celgene") and MetaStat, Inc., a Nevada corporation having an address at 27 Drydock Avenue, 2nd Floor, Boston, MA 02210-2377 ("Company").

Aduro BioTech – Patent and Technology License and Materials Transfer Agreement (March 11th, 2015)

THIS PATENT AND TECHNOLOGY LICENSE AND MATERIALS TRANSFER AGREEMENT (this Agreement) is dated as of January 31, 2013 (the Effective Date) and entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (JHU) and ADURO BIOTECH, INC., a Delaware corporation having an address at 626 Bancroft Way, Suite 3C, Berkeley, California 94710-2225 (Company):

Aduro BioTech – Patent and Technology License and Materials Transfer Agreement (March 2nd, 2015)

THIS PATENT AND TECHNOLOGY LICENSE AND MATERIALS TRANSFER AGREEMENT (this Agreement) is dated as of January 31, 2013 (the Effective Date) and entered into by and between THE JOHNS HOPKINS UNIVERSITY, a Maryland corporation having an address at 3400 N. Charles Street, Baltimore, Maryland, 21218-2695 (JHU) and ADURO BIOTECH, INC., a Delaware corporation having an address at 626 Bancroft Way, Suite 3C, Berkeley, California 94710-2225 (Company):

This Exhibit Has Been Redacted and Is the Subject of a Confidential Treatment Request. Redacted Material Is Marked With [* * *] and Has Been Filed Separately With the Securities and Exchange Commission. Materials Transfer Agreement by and Between Novavax, Inc. And Laboratorio Avi-Mex S.A. De C.V. Dated October 19, 2009 (November 9th, 2009)

This Materials Transfer Agreement (this Agreement) is entered into as of October 19, 2009 (the Effective Date) by and between Novavax, Inc., a corporation organized under the laws of Delaware, United States (Novavax) and Laboratorio Avi-mex, S.A. de C.V., a private company organized under the federal laws of Mexico (Avimex). Each of Novavax and Avimex may be collectively referred to as the Parties and each individually as a Party.

Nuvelo – University of Colorado Materials Transfer Agreement (May 15th, 2009)

This is an Agreement, dated October 14, 2005 (the Effective Date), between the Regents of the University of Colorado, a body corporate, contracting on behalf of the University of Colorado Health Sciences Center (UCHSC), and ARCA Discovery, Inc., a Delaware corporation with a principal place of business located at 1400 16th Street, Suite 220, Denver, CO 80202 (Recipient).

AdCare Health Systems, Inc. – Materials Transfer Agreement (February 8th, 2008)

This Materials Transfer Agreement (the Agreement), effective the 28th day of March, 2007 (Effective Date), is entered into by and between Kensey Nash Corporation, a Delaware corporation having its principal place of business at 735 Pennsylvania Drive, Exton, Pennsylvania 19341 (hereinafter KNC), and MiMedx, having offices at 1234 Airport Road, Destin, Florida 32541 (hereinafter MiMedx).

AdCare Health Systems, Inc. – Materials Transfer Agreement (February 8th, 2008)

This Materials Transfer Agreement (the Agreement), effective the 7th day of June, 2007 (Effective Date), is entered into by and between Kensey Nash Corporation, a Delaware corporation having its principal place of business at 735 Pennsylvania Drive, Exton, Pennsylvania 19341 (hereinafter KNC) and MiMedx, having offices at 1234 Airport Road, Destin, Florida 32541 (hereinafter MiMedx).

RealSource Residential, Inc – Materials Transfer Agreement (December 26th, 2007)

THIS AGREEMENT dated 7 December, 2007 is made by and between UPSTREAM BIOSCIENCES INC. (Upstream) and PROVINCIAL LAB FOR PUBLIC HEALTH (ProvLabs) represented by Dr. Stephanie Yanow (collectively, the Scientists).

RealSource Residential, Inc – Materials Transfer Agreement (December 26th, 2007)

THIS AGREEMENT dated 13 November, 2007 is made by and between UPSTREAM BIOSCIENCES INC. (Upstream) and MAKERERE UNIVERSITY, FACULTY OF VETERINARY MEDICINE (Makerere) represented by Prof. DAVID KABASA and DR. ENOCK MATOVU, DR. JOHN ENYARU (collectively, the Scientists).

Ocata Therapeutics, Inc. – Materials Transfer Agreement (May 23rd, 2005)

This Agreement is among Advanced Cell Technology, Inc. (ACT), Philip Damiani Ph.D. (The Institution) and CARLOS T. MORAES Ph.D. (Researcher). The Institution and the Researcher are collectively referred to in this Agreement as the Recipients.

Ocata Therapeutics, Inc. – University of Massachusetts Advanced Cell Technology Materials Transfer Agreement (May 23rd, 2005)

This Agreement is among the University of Massachusetts (UMass), Advanced Cell Technology, Inc. (ACT), University of Colorado (the Institution), and Curtis R. Freed, M.D. (Researcher). The Institution and the Researcher are collectively referred to in this Agreement as the Recipients.

Ocata Therapeutics, Inc. – Materials Transfer Agreement (May 23rd, 2005)

This Agreement is among Advanced Cell Technology, Inc. (ACT), and Charlotte Farin, Ph.D. and Peter Farin, D.V.M., Ph.D. (Dr. Charlotte Farin and Dr. Peter Farin collectively referred to herein as Researcher), professors at North Carolina State University in Raleigh, North Carolina (The Institution). The Institution and the Researcher are collectively referred to in this Agreement as the Recipients.

Ocata Therapeutics, Inc. – Materials Transfer Agreement (May 23rd, 2005)

This Agreement is among Advanced Cell Technology, Inc. (ACT), IPK (The Institution) and ANNA WOBUS IPK (Researcher). The Institution and the Researcher are collectively referred to in this Agreement as the Recipients.

Ocata Therapeutics, Inc. – Materials Transfer Agreement (May 23rd, 2005)

This Agreement is among Advanced Cell Technology, Inc. (ACT), B.C. Cancer Research Centre (The Institution) and Dr. Peter Lansdorp (Researcher). The Institution and the Researcher are collectively referred to in this Agreement as the Recipients.

Tapimmune Inc – Niaid Biological Materials Transfer Agreement (April 15th, 2005)

This Agreement is entered into by the National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health (NIH), which is part of the U.S. Public Health Service (PHS) and the Department of Health and Human Services (DHHS), an agency of the U.S. Government, having an address at 6610 Rockledge Drive, Room 4071, Bethesda, Maryland 20892, U.S.A. and GeneMax Pharmaceuticals Inc. (Recipient), a corporation of Delaware, having an office at 400 1681 Chestnut Street, Vancouver BC V6J 4M6, Canada.

Cabg Medical Inc – Materials Transfer Agreement Mayne Pharma (Usa) Inc (July 22nd, 2004)

Mayne Pharma (USA) Inc (Mayne) agrees to transfer the materials to CABG Medical, Inc. (Recipient) and Recipient agrees to use the Materials to carry out the Research Plan described below on terms and conditions agreed to between the Parties (Mayne and Recipient) and hereinafter appearing: